Several studies have suggested the multi-kinase inhibitor dasatinib—FDA-approved for treatment of chronic myeloid leukemia (CML) and Philadelphia (Ph) chromosome-positive ALL [6,7]—to be a promising targeted therapeutic agent in a distinct subtype of BCP-ALL, i.e., pre-B-cell receptor (pre-BCR)+/E2A-PBX1+ALL. This evidence concerns the gene PBX1 and chronic myelogenous leukemia, BCR-ABL1 positive.